DHPC | LPI
Other Brands
Local Prescribing Information (Rheumatology):
Tocilizumab Injection IV and SC [Actemra®]
Rituximab Injection [Ristova® and Ikgdar®]
Safety Update Information for Healthcare Professionals (Rheumatoid Arthritis):
Actemra® (Tocilizumab): A new Important Identified Risk: Hepatotoxicity
Local Prescribing Information (Nephrology):
Mycophenolate Mofetil Capsules I.P. [CellCept®]
Mycophenolate Mofetil Tablets I.P. [CellCept®]
Mycophenolate Mofetil Oral Suspension I.P. [CellCept®]
Local Prescribing Information (Antiviral):
Oseltamivir Phosphate Capsules I.P. [Tamiflu®]
Valganciclovir Tablets and Valganciclovir Powder for Oral Solution [Valcyte®]
Local Prescribing Information (Anaemia/ Haematology):
Epoetin beta Injection I.P. [NeoRecormon®]
Rituximab Injection [Ristova® and Ikgdar®]
Methoxy polyethylene glycol-epoetin beta Injection [Mircera®]
Disclaimer - Kindly note that it takes approximately up to 6 months to implement the revised PI in commercial stocks imported into India after submission to the health authorities. All PIs notified to or approved by the CDSCO are published on this website for all the HCPs prescribing Roche drugs within 10 calendar days.